Milestone Pharmaceuticals Launches RESET-PSVT Registry Study

Milestone Pharmaceuticals has initiated the RESET-PSVT registry study, designed to gather real-world evidence on the efficacy and safety of CARDAMYST™ (etripamil) nasal spray. This study focuses on patients experiencing paroxysmal supraventricular tachycardia (PSVT). The presentation of the study design at the Preventive Cardiovascular Nurses Association 2026 Cardiovascular Nursing Symposium highlights the company's commitment to advancing understanding of PSVT management. The registry aims to provide valuable data for healthcare providers and patients regarding the use of etripamil nasal spray in clinical settings.